References
- Torre LA, Bray F, Siegel RL, et al. Global cancer statistics; 2012. CA Cancer J Clin 2015;65:87-108
- Chen W, Zheng R, Baade PD, et al. Cancer statistics in China; 2015. CA Cancer J Clin 2016;66:115
- Dvm AJ, Siegel MR, Ward E, et al. Cancer statistics; 2007. CA Cancer J Clin 2003;53:225-49
- Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance; epidemiologic; and end results database. J Clin Oncol 2006;24:4539-44
- Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network Jnccn 2017;15:504
- Gentzler RD, Patel JD. Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications. Ther Adv Med Oncol 2014;6:4-15
- Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised; double-blind; phase 3 study. Lancet 2009;374:1432
- Si X. Research on the disease burden of lung cancer patiens and the effect of health insurance system in Wuhan. Wuhan: Huazhong University of Science and Technology; 2010
- Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895-902
- Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer 2006;95:683-90
- Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008;6:84
- Beusterien KM, Davies J, Leach M, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual of Life Outcomes 2010;8:50
- Zeng X, Peng L, Li J, et al. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system. Clin Ther 2013;35:54-65
- Li X, Wang Y, Yan W, et al. Supportive care costs associated with second-line chemotherapy in Chinese patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study. Drugs Real World Outcomes 2015;2:87
- Li Y, Wu Q, Xu L, et al. Factors affecting catastrophic health expenditure and impoverishment from medical expenses in China: policy implications of universal health insurance. Bull WHO 2012;90:664-71
- Qin-Chi W. To eliminate the financing demand of catastrophic medical expenditure and its effect on poverty reduction. Health Econ Res 2016;33:31-4
- Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 2003;1:8
- NBS. Statistical communiqué of the People’s Republic of China on the 2016 national economic and social development [EB/OL]. 2017. Available at: http://www.stats.gov.cn/tjsj/zxfb/201702/t20170228_1467424.html
- Xu B, Liu P, Yin Y, et al. Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer. Biomed Pharmacother 2013;67:763-9
- Pujol JL, Paz-Ares L, de Marinis F, et al. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2014;15:418-25
- Clarkson EB, Linley A, Frank JS, et al. The implementation of a patient assistance program in a free clinic setting: a case report. J Health Care Poor Underserved 2016;27:1183-91
- Clay P, Vaught E, Glaros A, et al. Costs to physician offices of providing medications to medically indigent patients via pharmaceutical manufacturer prescription assistance programs. J Manag Care Pharm 2007;13:506-14